CNTX — Context Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1842952 ·
Last close
$0.17
Market Cap
$15.71M
52W High
$3.62
52W Low
$0.15
ADV30
1,418,852
Next earnings
—
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,961,408 -7,623,706 36,537,920 34,410,919 5,532,662
Jun 2026 0 — -14,967,491 -14,558,426 46,134,154 42,990,371 7,962,103
Mar 2026 0 — -9,343,799 -8,680,572 58,859,093 54,528,596 6,656,718
Dec 2025 0 — -13,804,646 -13,025,607 68,493,768 65,995,228 8,020,041

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-33,971,518
Investing CF
$-8,555,746
Financing CF
$0
CapEx
$-8,555,746
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-161,766,013
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-46,077,344
Pretax Income TTM
$-43,888,311
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -39,702,631 -36,123,615 68,493,768 8,020,041 60,473,727 -26,385,380
Dec 2024 0 -29,923,900 -26,725,104 98,126,759 2,860,497 95,266,262 -14,556,434
Dec 2023 0 -25,072,616 -23,964,211 16,062,735 4,191,715 11,871,020 -21,047,618
Dec 2022 0 -14,881,203 -14,835,939 37,965,943 3,207,577 34,758,366 -13,549,234
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$2,455,058
NetIncome TTM
$-45,957,842
OpCashFlow TTM
—
Assets (Latest)
$46,134,154
Forward EPS
$-0.42

Peers — same industry

TickerNameMarket CapLastDaily %
NCEL NewcelX Ltd. $15.48M $2.68 —
QNRX Quoin Pharmaceuticals Ltd. $16.14M $3.36 —
VICP Vicapsys Life Sciences, Inc. $16.19M $0.50 —
MDNAF Medicenna Therapeutics Corp. $14.77M $0.16 —
BOLT Bolt Biotherapeutics, Inc. $14.73M $5.65 —

News headlines (Yahoo Finance, 1h cache)

Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
2026-11-10 21:16 · Yahoo
Context drops bispecific T-cell engager on cost-cutting initiative
2026-08-07 11:05 · Yahoo
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:05 · Yahoo
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-07-06 20:07 · Yahoo
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
2026-06-15 10:30 · Yahoo
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
2026-06-15 15:10 · Yahoo
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 10:45 · Yahoo
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
2026-05-06 20:18 · Yahoo
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
2026-04-02 11:30 · Yahoo
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
2026-05-27 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.